CASC Cascadian Therapeutics, Inc. (delisted)

Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Tuesday, March 10, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its full year and fourth quarter 2014 financial results.

To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the "Events" page of the "News & Events" section of Oncothyreon's website at www.oncothyreon.com. An archive of the webcast will be available after completion of the discussion and will be posted on the Oncothyreon website.

About Oncothyreon

Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our current clinical-stage product candidates include ONT-380, an orally active and selective small molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting MUC1. We are developing preclinical product candidates in oncology, and potentially certain rare diseases, using our protocell technology. For more information, visit www.oncothyreon.com.

CONTACT: Investor and Media Relations Contact:
         Julie Rathbun
         Rathbun Communications
         206-769-9219
         ir@oncothyreon.com